DOW JONES23,719.37+285.80 1.22%
S&P 5002,789.82+39.84 1.45%
NASDAQ8,153.58+62.67 0.77%

H.C. Wainwright Reiterates Buy on Jounce Therapeutics, Lowers Price Target to $10

H.C. Wainwright analyst Debjit Chattopadhyay reiterates Jounce Therapeutics (NASDAQ:JNCE) with a Buy and lowers the price target from $13 to $10.

Benzinga · 03/02/2020 12:35

H.C. Wainwright analyst Debjit Chattopadhyay reiterates Jounce Therapeutics (NASDAQ:JNCE) with a Buy and lowers the price target from $13 to $10.